10 Amendments of Tudor CIUHODARU related to 2019/2816(RSP)
Amendment 41 #
Recital B
B. whereas the wide use of pharmaceuticals in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the largest source of pharmaceuticals entering the environment is their use andexcessive use without medical supervision, followed by their disposal;
Amendment 42 #
Recital C
C. whereas pharmaceuticals reach the environment through the discharge of effluent from urban wastewater treatment plants, the spreading of animal manure and aquaculture, discharge of effluent from manufacturing plants, the spreading of sewage sludge, grazing livestock, the treatment of pets, improper disposal into landfill of unused pharmaceuticals and contaminated waste and their further dissemination by sometimes heavy rainfall;
Amendment 80 #
Paragraph 3
3. Notes however with concern the very soft nature of the measures included in the communication; considers that legislative measures are needed in addition to non-legislative measures to properly tackle pharmaceutical pollution at European level;
Amendment 91 #
Paragraph 5 a (new)
5a. Considers it necessary to organise, in collaboration with the Member States, campaigns to inform and educate the public about the dangers of over- consumption of non-prescribed medicines; draws attention to the increase in the number of supermarket and online sales of medicines without medical recommendation and to the danger of media advertising for such points of sale outside of pharmacies or suitably accredited establishments;
Amendment 98 #
Paragraph 7
7. Recalls that studies have shown that pharmaceutical products are especially present in water bodies, and that they are ineffectively filtered by wastewater treatment plants, requiring periodic adaptation of purification processes in line with the new products and technologies on the market;
Amendment 143 #
Paragraph 13 a (new)
13a. Stresses that health professionals must be kept continuously up to date regarding the latest developments in research and good practices when it comes to preventing the spread of AMR;
Amendment 146 #
Paragraph 14
14. Highlights the importance of the design, development and manufacturing phases to minimise the environmmore rapid, ambitious and targeted measures to reduce the environmental risks posed by pharmaceuticals, while acknowledging the need for further research for a better understanding of the extent of the currental impact of pharmaceuticals on human health and the environment;
Amendment 171 #
Paragraph 18
18. Calls for monitoring data from the Water Framework Directive to include suitable parameters regarding the impact of pharmaceuticals that must be used for post-market evaluation;
Amendment 190 #
Paragraph 24
24. Considers it appropriate that pharmaceutical companies submit a joint environmental risk assessment per active substance, including the time necessary for the disappearance of these substances from the environment, based on half-life calculations for radioactive substances, so as to have coherent information, avoid duplication of work and reduce animal testing;
Amendment 230 #
Paragraph 32
32. Is concerned that monitoring of pharmaceuticals in the environment is still very limited; stresses the need to strengthen post-marketing control mechanisms intothrough comprehensive monitoring, also with regard to environmental effectswith the introduction of new indicators where necessary, including environmental impact monitoring, as the current surveillance system (pharmacovigilance) is not adequately and systematically covering the environmental data deficit;